Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 09:00 ET | Source: project44

Hormuz Disruption Triggers 34,000 Diversions as New Transshipment Hubs Emerge Across Asia

project44 report finds 34K+ Hormuz diversions reshaping trade flows and driving worsening port congestion with no easing in sight.
March 31, 2026 08:55 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3...
March 31, 2026 08:55 ET | Source: Kela Research and Strategy

KELA Group Reports Over 100% YoY Growth Driven by Enterprise Demand for Consolidated, AI-Driven Active Cyber Defense

Tel Aviv, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- NEW YORK, NY and TEL AVIV, ISRAEL – March 31, 2026 – KELA Group, a global leader in Cyber Threat Intelligence and Exposure Management, today...
March 31, 2026 08:05 ET | Source: Regula Forensics

The Metrics Used to Stop Identity Fraud Are Falling Behind, Regula Study Finds

Regula study: outcome-based fraud KPIs are failing. Businesses shift to proactive metrics: compliance, ROI, and real-time fraud detection.
March 31, 2026 08:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve...
March 31, 2026 08:00 ET | Source: Pheast Therapeutics

Pheast Therapeutics Advances PHST001, an IgG4 Anti-CD24 Monoclonal Antibody, into Phase 1b Combination Cohorts

First patient dosed in Phase 1b portion of ongoing Phase 1 study evaluating PHST001 in combination with chemotherapy Company to present three abstracts at AACR 2026, including preliminary clinical...
March 31, 2026 08:00 ET | Source: Sophos Inc.

Only 5% of organizations have full trust in their cybersecurity vendors

OXFORD, United Kingdom, March 31, 2026 (GLOBE NEWSWIRE) -- Sophos, a global leader of innovative security solutions for defeating cyberattacks, today released findings from a global, vendor-agnostic...
March 31, 2026 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and...
March 31, 2026 08:00 ET | Source: Imunon, Inc.

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2...
March 31, 2026 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for...